Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vsee Health (VSEE) EBITDA (2023 - 2025)

Vsee Health's EBITDA history spans 3 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 201.35% year-over-year to $3.1 million; the TTM value through Dec 2025 reached -$3.1 million, up 94.99%, while the annual FY2025 figure was -$3.1 million, 95.05% up from the prior year.
  • EBITDA reached $3.1 million in Q4 2025 per VSEE's latest filing, up from -$2.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.1 million in Q4 2025 to a low of -$58.3 million in Q3 2024.
  • Average EBITDA over 3 years is -$6.0 million, with a median of -$715855.0 recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 16411.08% in 2024, then skyrocketed 201.35% in 2025.
  • A 3-year view of EBITDA shows it stood at -$114831.0 in 2023, then tumbled by 2536.38% to -$3.0 million in 2024, then surged by 201.35% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for VSEE's EBITDA are $3.1 million (Q4 2025), -$2.1 million (Q3 2025), and -$2.3 million (Q2 2025).